#USA #pharmaceuticals #Upsher-Smith #Maple Grove #CiproDex

Upsher-Smith Launches Generic CiproDex® Eye Drops

Upsher-Smith Laboratories, an entity of Bora Pharmaceuticals, has recently unveiled its generic version of CiproDex® (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Otic Suspension, marking a pivotal step in the company's efforts to diversify its product offerings. As part of Upsher-Smith's strategic roadmap, this launch aims to cater to the significant market demand for prescription ear drop solutions.

The U.S. market for Ciprofloxacin and Dexamethasone Otic Suspension has seen substantial sales, reaching approximately $118 million, according to IQVIA. This development is expected to enhance Upsher-Smith's presence in a market that has consistently sought high-quality generics to meet patient healthcare needs.

Jim Maahs, Senior Vice President and Head of Upsher-Smith Commercial, emphasized the importance of this launch during a recent statement. He noted, "The introduction of our first prescription ear drop suspension reinforces our strategic focus on expanding and diversifying our generics portfolio to support sustainable, long-term growth." This sentiment underscores the company's commitment to patients and their healthcare providers by providing alternative solutions that not only meet therapeutic needs but also support accessibility in healthcare.

The newly launched product, Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, holds significant therapeutic equivalence with existing branded products, categorizing it under the TE code AB. The reference listed drug for this product is the well-known Ciprodex®.

The technical specifications of this new offering include:

• - Composition: 0.3% Ciprofloxacin and 0.1% Dexamethasone
• - NDC #: 0832-1430-75
• - Package Size: 7.5 mL

For healthcare professionals and pharmacists interested in ordering, Upsher-Smith provides a direct line at 1-800-654-2299, accompanied by a complete Prescribing Information document available for access. Additionally, inquiries regarding adverse reactions can be made to the company's dedicated line or through the FDA's reporting portal.

Upsher-Smith Laboratories has established itself as a trusted name in the pharmaceutical industry, with a mission to enhance the health and lives of patients. The company’s rigorous commitment to high-quality generic medications aligns with its core objectives to provide accessible healthcare options. Furthermore, as a component of the Bora Group, founded in 2007, Upsher-Smith is poised to continue evolving and expanding its market reach through strategic partnerships and innovative product developments.

Bora Pharmaceuticals promotes a dual-engine approach combining Contract Development and Manufacturing Organization (CDMO) expertise with commercial capabilities to facilitate better health outcomes globally. By investings in technology, talent, and infrastructure, Bora seeks to respond effectively to pharmaceutical and biotech partners, enhancing the product development process and accelerating market entries for crucial health products.

The launch of the generic version of CiproDex® is not only a win for Upsher-Smith but also for patients who will benefit from the availability of more affordable healthcare solutions. As the demand for such generic products continues to rise, Upsher-Smith is well-positioned to cater to these market dynamics while maintaining its pledge toward high quality and reliable service. Through ongoing innovation and an emphasis on patient care, Upsher-Smith reaffirms its role as a significant player in the generic pharmaceuticals arena.